-- Surgery 2 Question Bank: Topic 46 - Prostate Disorders (32 MCQs)
-- Category: Surgery 2 (a0000002-0000-0000-0000-000000000002)
-- Topic: Prostate Disorders (c2000046-0000-0000-0000-000000000046)

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES
('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The prostate gland is located:', 'Superior to the bladder', 'Inferior to the bladder, surrounding the prostatic urethra', 'In the scrotum', 'Behind the rectum', 'In the perineum only', 'B', 'Prostate: surrounds prostatic urethra below bladder neck. Base is superior (bladder), apex inferior (urogenital diaphragm). Posterior to it is rectum (DRE). Seminal vesicles posterosuperior.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The zones of the prostate according to McNeal include all EXCEPT:', 'Peripheral zone', 'Transition zone', 'Central zone', 'Posterior zone', 'Anterior fibromuscular stroma', 'D', 'McNeal zones: peripheral (70% - most cancers), central (25% - surrounds ejaculatory ducts), transition (5% - BPH), anterior fibromuscular stroma (no glands). No posterior zone.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Benign prostatic hyperplasia (BPH) arises primarily from the:', 'Peripheral zone', 'Transition zone', 'Central zone', 'Anterior stroma', 'Capsule', 'B', 'BPH arises from transition zone (periurethral). Causes urethral compression and LUTS. Prostate cancer typically arises from peripheral zone (palpable on DRE).', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Lower urinary tract symptoms (LUTS) in BPH include:', 'Haematuria always', 'Storage symptoms (frequency, urgency, nocturia) and voiding symptoms (hesitancy, weak stream)', 'Back pain', 'Weight loss', 'Fever', 'B', 'LUTS: storage (irritative) - frequency, urgency, nocturia, urge incontinence. Voiding (obstructive) - hesitancy, weak stream, intermittency, straining, incomplete emptying, terminal dribbling.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'International Prostate Symptom Score (IPSS) is used to:', 'Diagnose prostate cancer', 'Quantify LUTS severity and monitor treatment response', 'Stage prostate cancer', 'Measure prostate size', 'Detect urinary infection', 'B', 'IPSS: 7 symptom questions (0-35) + quality of life. Mild (0-7), moderate (8-19), severe (20-35). Used to quantify symptoms, guide treatment, monitor response. Not diagnostic for specific pathology.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Digital rectal examination in BPH typically reveals:', 'Hard nodular prostate', 'Smooth, enlarged, rubbery prostate', 'Tender prostate', 'Normal prostate', 'Absent prostate', 'B', 'BPH on DRE: smooth, enlarged, rubbery, symmetric. Median sulcus may be obliterated. Cancer: hard, nodular, irregular. Prostatitis: tender. DRE doesnt correlate well with symptom severity.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'First-line medical treatment for BPH includes:', 'Antibiotics', 'Alpha-1 blockers (tamsulosin) and/or 5-alpha reductase inhibitors (finasteride)', 'Chemotherapy', 'Antimuscarinics only', 'Opioids', 'B', 'BPH medications: alpha-blockers (rapid symptom relief - relaxes smooth muscle), 5-ARIs (shrinks prostate over months - large glands), combination for moderate-severe. PDE5 inhibitors also effective.', 'easy', 'application'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Alpha-blockers for BPH work by:', 'Shrinking the prostate', 'Relaxing prostatic and bladder neck smooth muscle', 'Killing cancer cells', 'Increasing testosterone', 'Reducing inflammation', 'B', 'Alpha-1 blockers (tamsulosin, alfuzosin): relax smooth muscle of prostate capsule, bladder neck, prostatic urethra. Rapid onset (days). Side effects: postural hypotension, retrograde ejaculation.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, '5-alpha reductase inhibitors work by:', 'Relaxing smooth muscle', 'Blocking conversion of testosterone to DHT, reducing prostate size', 'Direct cytotoxic effect', 'Increasing bladder capacity', 'Stimulating urination', 'B', '5-ARIs (finasteride, dutasteride): block testosterone → DHT conversion. Reduce prostate volume by 20-30%. Slow onset (3-6 months). Best for large prostates (>40g). Reduce PSA by 50%.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Indications for surgical treatment of BPH include:', 'All patients with BPH', 'Refractory retention, recurrent UTI, bladder stones, renal impairment, or failed medical therapy', 'Mild LUTS only', 'Elevated PSA', 'Young age', 'B', 'Surgery indications: absolute - refractory retention, recurrent UTI, bladder stones, renal impairment, gross haematuria. Relative - failed medical therapy, moderate-severe symptoms, patient preference.', 'medium', 'application'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'TURP (transurethral resection of prostate) is:', 'Open surgery', 'Endoscopic resection of prostatic tissue - gold standard for moderate-sized BPH', 'Laser ablation', 'Medication', 'External beam therapy', 'B', 'TURP: transurethral resection using electrocautery loop. Gold standard for moderate prostates (30-80g). Effective, durable. Complications: bleeding, TUR syndrome (hyponatraemia), retrograde ejaculation.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'TUR syndrome is caused by:', 'Infection', 'Absorption of hypotonic irrigation fluid causing dilutional hyponatraemia', 'Blood loss', 'Urethral stricture', 'Incontinence', 'B', 'TUR syndrome: absorption of irrigation fluid (glycine) during TURP. Causes dilutional hyponatraemia, fluid overload. Symptoms: confusion, nausea, hypertension, bradycardia, seizures. Treatment: stop procedure, saline, diuretics.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Alternative surgical options for BPH include all EXCEPT:', 'Holmium laser enucleation (HoLEP)', 'Greenlight laser (PVP)', 'Simple prostatectomy', 'Radical prostatectomy', 'UroLift', 'D', 'BPH surgery options: TURP, HoLEP (large glands), laser PVP, open simple prostatectomy (very large), minimally invasive (UroLift, Rezum). Radical prostatectomy is for cancer, not BPH.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Prostate cancer is the _____ most common cancer in men:', 'First', 'Second', 'Third', 'Fifth', 'Tenth', 'B', 'Prostate cancer: 2nd most common cancer in men globally (after lung), most common in many Western countries. Lifetime risk ~15%. Most are indolent. Incidence increases with age.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Risk factors for prostate cancer include:', 'Young age', 'Age, family history, and African ancestry', 'Low testosterone', 'Vegetarian diet', 'High physical activity', 'B', 'Risk factors: age (strongest - rare <50), family history (2-3x if first-degree relative), African ancestry (higher incidence and mortality), genetic (BRCA2). Diet (Western) possibly contributory.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'PSA (prostate-specific antigen) is:', 'Specific for prostate cancer', 'Prostate-specific but not cancer-specific; can be elevated in BPH, prostatitis, and cancer', 'A hormone', 'Only elevated in metastatic disease', 'Normal if cancer present', 'B', 'PSA: serine protease, prostate-specific (not cancer-specific). Elevated in: cancer, BPH, prostatitis, instrumentation. Normal <4ng/mL (age-adjusted values exist). Used for screening (controversial) and monitoring.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Prostate biopsy is typically performed:', 'Transabdominally', 'Transrectally or transperineally under ultrasound guidance', 'Via open surgery', 'Through the urethra', 'Laparoscopically', 'B', 'Prostate biopsy: TRUS-guided (transrectal) historically standard. Transperineal increasingly preferred (lower infection risk). Systematic biopsies, targeted with MRI-fusion. For diagnosis when cancer suspected.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Gleason score in prostate cancer:', 'Stages the cancer', 'Grades the cancer based on histological pattern (differentiation)', 'Measures PSA', 'Indicates prognosis only', 'Determines treatment', 'B', 'Gleason score: histological grading. Sum of two most common patterns (1-5 each). Range 6-10 (well to poorly differentiated). Now reported as Grade Group (1-5). Higher grade = more aggressive.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Multiparametric MRI of the prostate is used for:', 'Treatment of prostate cancer', 'Detection, localization, and staging of prostate cancer', 'BPH diagnosis', 'Infection detection', 'Measuring PSA', 'B', 'mpMRI: T2-weighted, diffusion-weighted (DWI), dynamic contrast enhancement (DCE). Detects clinically significant cancer, guides biopsy (targeted), staging. PI-RADS scoring system.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Localized low-risk prostate cancer may be managed by:', 'Immediate chemotherapy', 'Active surveillance', 'Palliative care only', 'Bilateral orchiectomy', 'Radiation only', 'B', 'Low-risk prostate cancer (Gleason ≤6, PSA <10, T1-T2a): active surveillance appropriate - monitoring with PSA, DRE, repeat biopsy, MRI. Avoids overtreatment. Intervention if progression.', 'medium', 'application'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Curative treatment options for localized prostate cancer include:', 'Hormone therapy alone', 'Radical prostatectomy or radiotherapy', 'Chemotherapy', 'Watchful waiting only', 'Palliative care', 'B', 'Localized prostate cancer treatment: radical prostatectomy (open, laparoscopic, robotic), radiotherapy (EBRT, brachytherapy). Choice depends on risk, patient factors, preference. Similar oncological outcomes.', 'medium', 'application'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Major complications of radical prostatectomy include:', 'TUR syndrome', 'Erectile dysfunction and urinary incontinence', 'Bowel obstruction', 'Pulmonary fibrosis', 'Thyroid dysfunction', 'B', 'Radical prostatectomy complications: erectile dysfunction (nerve injury - 20-70%), urinary incontinence (5-20% long-term), lymphocele, anastomotic stricture. Nerve-sparing technique preserves potency.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Androgen deprivation therapy (ADT) for prostate cancer works by:', 'Direct cytotoxicity', 'Reducing testosterone which prostate cancer cells need for growth', 'Boosting immunity', 'Blocking cell division', 'Reducing inflammation', 'B', 'ADT: prostate cancer is androgen-dependent. Reduces testosterone: LHRH agonists (leuprolide - initial flare), LHRH antagonists (degarelix - no flare), bilateral orchiectomy. Castrate testosterone <50ng/dL.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Side effects of androgen deprivation therapy include all EXCEPT:', 'Hot flushes', 'Osteoporosis', 'Gynecomastia', 'Increased muscle mass', 'Metabolic syndrome', 'D', 'ADT side effects: hot flushes, decreased libido, erectile dysfunction, fatigue, osteoporosis, metabolic syndrome, cardiovascular risk, cognitive effects, gynecomastia. Muscle loss, not gain.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Castration-resistant prostate cancer (CRPC) is defined as:', 'Cancer responding to castration', 'Cancer progressing despite castrate testosterone levels', 'Metastatic cancer only', 'Low-grade cancer', 'Cancer with normal PSA', 'B', 'CRPC: disease progression (rising PSA and/or imaging progression) despite testosterone <50ng/dL. Treatment options: novel hormonal agents (abiraterone, enzalutamide), chemotherapy (docetaxel), targeted therapy.', 'hard', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Prostate cancer most commonly metastasizes to:', 'Liver', 'Bone (axial skeleton)', 'Lung', 'Brain', 'Spleen', 'B', 'Prostate cancer bone mets: most common site. Typically osteoblastic (sclerotic). Axial skeleton (spine, pelvis). Bone scan for detection. Can cause pain, fractures, cord compression.', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Acute bacterial prostatitis presents with:', 'Chronic pelvic pain', 'Fever, dysuria, perineal pain, and tender prostate on DRE', 'Painless urinary retention', 'Haematuria only', 'No symptoms', 'B', 'Acute prostatitis: systemic illness - fever, chills, malaise. Urinary symptoms - dysuria, frequency, retention. Perineal/suprapubic pain. DRE: very tender, boggy prostate. Avoid vigorous exam (bacteremia).', 'easy', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Treatment of acute bacterial prostatitis is:', 'Alpha-blockers alone', 'Prolonged antibiotic therapy (fluoroquinolones or TMP-SMX for 4-6 weeks)', 'Surgery', 'Observation', 'Antimuscarinics', 'B', 'Acute prostatitis treatment: IV antibiotics if septic, then oral fluoroquinolone or TMP-SMX for 4-6 weeks (prostate penetration). Supportive care. May need catheter if retention (suprapubic preferred).', 'medium', 'application'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Chronic pelvic pain syndrome (CPPS/chronic prostatitis) is characterized by:', 'Positive urine culture', 'Pelvic pain for ≥3 months without evidence of infection', 'Acute onset', 'Fever', 'Positive blood cultures', 'B', 'CPPS (NIH category III): most common prostatitis type. Chronic pelvic pain ≥3 months, no bacteria on culture. Inflammatory (IIIA) or non-inflammatory (IIIB). Treatment multimodal: alpha-blockers, NSAIDs, physiotherapy.', 'medium', 'knowledge'),

('c2000046-0000-0000-0000-000000000046'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Prostatic abscess typically occurs in:', 'Healthy young men', 'Diabetics, immunocompromised, or with chronic catheterization', 'All prostatitis cases', 'Post-vasectomy', 'Only elderly', 'B', 'Prostatic abscess: rare complication of prostatitis. Risk factors: diabetes, immunosuppression, chronic catheters, recent instrumentation. Diagnosis: transrectal US or CT. Treatment: antibiotics + drainage.', 'medium', 'knowledge');
